Drug intelligence / Profile preview

Betuvax-CoV-2

Development stage: Phase 2
Lead developer: Artgen Biotech
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Betuvax-CoV-2 is a recombinant protein subunit vaccine for COVID-19 based on the S-protein RBD fused with the Fc-fragment of IgG. It uses spherical particles with a betulin-based adjuvant to enhance immunogenicity. The vaccine does not contain inactivated or weakened virus particles, vector viruses, genetic material (RNA or DNA), or inorganic adjuvants, making it potentially suitable for multiple revaccinations with minimal adverse reactions. Clinical trials have shown it to be safe and capable of inducing a strong humoral immune response.

Brand names: Betuvax-CoV-2Betuvax-CoV2Betuvax-CoV 2
Other names: БетуваксBetuvax

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on Betuvax-CoV-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Betuvax-CoV-2.

Explore the full profile